Surgical Outcomes in Splenic Flexure Cancers: A Multicenter Comparison of Segmental vs. Extended Hemicolectomy (SPARROW Study) (SPARROW)

December 15, 2025 updated by: Acibadem University

Surgical Outcomes in Splenic Flexure Cancers: A Prospective, Multicentric Observational Cohort Study Comparing Segmental Hemicolectomy and Extended Hemicolectomy - The SPARROW Study

SPARROW Study: Surgical Outcomes in Splenic Flexure Cancer

Colonic cancers located at the splenic flexure where the transverse colon turns into the descending colon are uncommon and represent less than 10% of all colorectal cancers. Because of their unique location between the blood supply of the right and left colon, there is no clear agreement on which surgical method provides the best results.

Two main procedures are used:

Segmental hemicolectomy, which removes only the part of the colon containing the tumor, and

Extended hemicolectomy, which removes a larger section of the colon and more lymph nodes.

The SPARROW Study is a prospective, multicenter observational study designed to compare these two surgical approaches in patients with splenic flexure cancer. The study will include about 140 patients (70 in each group) from multiple tertiary colorectal centers in Turkey and Europe.

Researchers will collect information about each patient's surgery, recovery, and follow-up outcomes. The main outcomes include postoperative ileus, leakage at the surgical connection (anastomosis), wound infection, and total postoperative complications. Other outcomes include number of lymph nodes removed, complete tumor resection (R0), hospital stay, recovery time, reoperation, and 3-year overall and disease-free survival.

By analyzing both short- and long-term results, the SPARROW Study aims to provide high-quality evidence to guide surgeons in choosing the best and safest operation for patients with splenic flexure cancers.

All participants will provide written informed consent before joining the study. The study has received ethical approval from the Koç University Ethics Committee and will be conducted in accordance with the Declaration of Helsinki.

Study Overview

Status

Enrolling by invitation

Conditions

Intervention / Treatment

Detailed Description

Study Rationale:

Splenic flexure cancers pose unique surgical challenges due to their variable blood supply and lymphatic drainage. The optimal extent of resection remains controversial, with both extended right and left colectomy approaches showing different technical advantages. However, there are no prospective multicenter data comparing their perioperative and oncologic outcomes.

Study Design:

This is a prospective, multicenter observational cohort study involving tertiary colorectal cancer centers. The study will enroll 140 consecutive adult patients (≥18 years old) undergoing elective curative resection for histologically confirmed splenic flexure adenocarcinoma. Surgical approach-segmental or extended colectomy-will be chosen according to the operating surgeon's routine practice and preference, not assigned by randomization.

Primary Outcomes:

Postoperative ileus (incidence and duration)

Anastomotic leakage

Wound infection

Total postoperative complications

Secondary Outcomes:

Lymph node yield and R0 resection rate

Postoperative mortality

Operation time and estimated blood loss

Hospital stay, return to regular diet, and time to first flatus

Reoperation rates

3-year overall survival (OS) and disease-free survival (DFS)

Timeline:

Study start: 2025

Enrollment period: 24 months

Follow-up: 36 months per patient

Total duration: approximately 5 years

Ethical Conduct:

Ethical approval was obtained from the Koç University Ethics Committee. Each participating center will obtain local ethics approval. The study adheres to the principles of the Declaration of Helsinki and Good Clinical Practice (GCP).

Expected Impact:

This will be the first prospective multicenter observational study to compare segmental and extended hemicolectomy for splenic flexure cancers. The results will help standardize surgical decision-making and improve patient outcomes for this uncommon and technically challenging tumor location.

Study Type

Observational

Enrollment (Estimated)

140

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Turkey (Türkiye)
    • Istanbul
      • Istanbul, Istanbul, Turkey (Türkiye), 34752
        • Acibadem University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

This study will include adult patients diagnosed with splenic flexure adenocarcinoma who undergo elective curative resection (segmental or extended hemicolectomy) at participating tertiary colorectal surgery centers in Turkey and Europe. All patients will be treated according to the surgeon's standard practice and institutional protocols. Data will be collected prospectively for both perioperative and follow-up outcomes as part of the multicenter SPARROW Study.

Description

Inclusion Criteria:

  • Adult patients aged 18 years or older
  • Histologically confirmed adenocarcinoma of the splenic flexure
  • Elective surgical resection performed with curative intent (segmental colectomy or extended hemicolectomy)
  • Availability of complete perioperative and follow-up data
  • Written informed consent provided prior to participation
  • Surgery performed by colorectal or general surgeons meeting institutional eligibility criteria (≥20 colorectal cancer cases/year, ≥2 years of colorectal training)

Exclusion Criteria:

  • Emergency surgery for obstruction, perforation, or bleeding
  • Non-adenocarcinoma histology (e.g., lymphoma, neuroendocrine tumor, gastrointestinal stromal tumor)
  • Patients undergoing palliative resections, local excisions, or bypass procedures without curative intent
  • Presence of synchronous colorectal malignancy or distant metastasis requiring simultaneous resection
  • Previous colorectal resection involving the splenic flexure
  • Patients with incomplete clinical or pathological data or those lost to follow-up before 30 days postoperatively

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Incidence of Postoperative Ileus After Surgery for Splenic Flexure Cancer
Time Frame: Within 30 days after surgery
The presence of postoperative ileus will be evaluated as the main indicator of early perioperative recovery. Ileus is defined as intolerance to oral intake and absence of bowel function beyond the expected postoperative period, requiring nasogastric decompression or delayed diet advancement. Data will be collected from medical records and postoperative progress notes. Additional related variables-such as the duration of ileus, need for nasogastric tube reinsertion, and time to first flatus-will also be recorded.
Within 30 days after surgery

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Acibadem University

Investigators

  • Principal Investigator: Bilgi Baca, MD, Professor of Surgery, Acibadem University Istanbul Turkey

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 5, 2025

Primary Completion (Estimated)

October 1, 2028

Study Completion (Estimated)

October 1, 2030

Study Registration Dates

First Submitted

November 18, 2025

First Submitted That Met QC Criteria

December 15, 2025

First Posted (Actual)

December 17, 2025

Study Record Updates

Last Update Posted (Actual)

December 17, 2025

Last Update Submitted That Met QC Criteria

December 15, 2025

Last Verified

October 1, 2025

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 2025.249.IRB2.115

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

De-identified individual participant data (IPD) underlying the published results will be shared, including baseline demographic information, surgical approach (segmental vs. extended hemicolectomy), operative characteristics, short-term perioperative outcomes, and follow-up survival data. No directly identifiable information (such as names, contact details, or institutional identifiers) will be included. Data will be available in a secure, de-identified format for qualified researchers upon reasonable request to the SPARROW Study Steering Committee through the Turkish Society of Colon and Rectal Surgery (TKRCD), following approval of a data-use agreement and ethical review.

IPD Sharing Time Frame

De-identified individual participant data (IPD) and supporting materials will be available beginning 12 months after publication of the primary manuscript and will remain available indefinitely for qualified researchers upon reasonable request.

IPD Sharing Access Criteria

Qualified researchers affiliated with academic institutions, professional societies, or healthcare organizations may request access to the de-identified dataset, study protocol, statistical analysis plan, and informed consent form. Requests should be submitted in writing to the SPARROW Study Steering Committee via the Turkish Society of Colon and Rectal Surgery (TKRCD). Access will be granted after approval of the research proposal and signing of a data-use agreement ensuring ethical conduct, confidentiality, and non-commercial use. Data will be shared electronically through a secure, password-protected institutional platform.

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • SAP
  • ICF

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Colon Cancer

Clinical Trials on Colectomy

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Portugal

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe